The Role of Gut Microbiota in Drug Response

被引：83

作者：

Wilson, I. D. ^{[1
]}

Nicholson, J. K. ^{[2
]}

机构：

[1] AstraZeneca, Dept Clin Pharmacol Drug Metab & Pharmocokinet, Macclesfield SK10 4TG, Cheshire, England

[2] Univ London Imperial Coll Sci Technol & Med, Dept Biomol Med, Div Surg Oncol Reprod Biol & Anaesthet, Fac Med, London SW7 2AZ, England

来源：

CURRENT PHARMACEUTICAL DESIGN | 2009年 / 15卷 / 13期

关键词：

Drug metabolism; bioavailability; gut microbiota; superorganisms; population differences; diet; INTESTINAL MICROFLORA; GERM-FREE; GASTROINTESTINAL-TRACT; METABOLIC-ACTIVITY; FLORA; DIGOXIN; RATS; INACTIVATION; DIET; IDENTIFICATION;

D O I：

10.2174/138161209788168173

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Higher organisms such as mammals exist in a symbiotic relationship with their gut microbiota, formed from a diverse and highly metabolically active consortium of species. The gut microbiota, in addition to their ability to process dietary derived material, are also capable of performing a range of biotransformations on xenobiotics, such as drugs and their metabolites, in ways that can affect absorption and bioavailability. The potential for the gut microflora to influence drug metabolism and toxicity in unexpected ways is discussed.

引用

页码：1519 / 1523

页数：5

共 32 条

[1] INTESTINAL COLONIZATION WITH ENTEROBACTERIACEAE IN PAKISTANI AND SWEDISH HOSPITAL-DELIVERED INFANTS [J].